Sumitomo Pharma Co. Ltd (SMDPY PINK) stock market data APIs
$11.5011
0(0%)
as of December 17, 2025
Try our APIs with
free plan!
Sumitomo Pharma Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
Prev. Close
11.5011
Open
11.5011
High
11.5011
Low
11.5011
52 wk Range
4.1-11.45
Market Cap
5 370 M
P/E Ratio
4.5437
Shares Outstanding
397 M
Revenue
445 205 M
EPS
1.4961
Beta
0.533
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sumitomo Pharma Co. Ltd data using free add-ons & libraries
Get Sumitomo Pharma Co. Ltd Fundamental Data
Sumitomo Pharma Co. Ltd Fundamental data includes:
- Net Revenue: 445 205 M
- EBITDA: 139 168 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-28
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sumitomo Pharma Co. Ltd News
New
Is Sumitomo Pharma’s 344% 2025 Surge Still Supported by Its Fundamentals?
Wondering if Sumitomo Pharma's wild run has left the stock overhyped or still quietly undervalued? This breakdown will help you decide whether it deserves a spot on your radar. The share price has dip...
Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition
New investigational data from Phase 1/2 study of enzomenib (DSP-5336) in patients with relapsed/refractory acute myeloid leukemia (AML) show clinical activity in various leukemia subtypes driven by ge...
Tech, Central Bank Outlooks Mix Asian Stock Markets
Asian stock markets were uneven on Thursday, as traders weighed tech outlooks and an soft US jobs r PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
Poxel Reports Revenue for the Third Quarter 2025
TWYMEEG® sales continue to grow in Japan, up 5% in the last quarter (July-September) compared to the previous quarter and up 40% compared to the third quarter of 2024 Gross TWYMEEG® for Sumitomo Pha...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
